Literature DB >> 7363931

Relationship between blood and cerebrospinal levels of the antidepressant agent viloxazine.

O Elwan, H K Adam.   

Abstract

Viloxazine levels in blood and CSF have been measured following acute and chronic dosing in depressed patients. Blood profiles confirm previous findings that viloxazine is rapidly absorbed and eliminated with a half-life of 4.5 h. Viloxazine crosses the blood-brain barrier and concentrations in CSF remain virtually unchanged over a ten hour period post administration. Viloxazine does not accumulate in CSF on chronic administration. The fact that CSF levels do not reflect concentrations in blood has significant implications on any attempt to correlate the clinical efficacy and the pharmacokinetic behaviour of an antidepressant agent.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7363931     DOI: 10.1007/bf00561897

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Some preliminary observations on ICI 58 834, a new psychotropic agent, in man.

Authors:  M Kirby; P Turner
Journal:  Br J Clin Pharmacol       Date:  1974-04       Impact factor: 4.335

Review 2.  Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness.

Authors:  R M Pinder; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-06       Impact factor: 9.546

3.  Plasma nortriptyline and clinical response.

Authors:  G Burrows; B A Scoggins; L R Turecek; B Davies
Journal:  Clin Pharmacol Ther       Date:  1974-10       Impact factor: 6.875

4.  Plasma concentration of amitriptyline and clinical response.

Authors:  R A Braithwaite; R Goulding; G Theano; J Bailey; A Coppen
Journal:  Lancet       Date:  1972-06-17       Impact factor: 79.321

5.  Plasma-nortriptyline levels in endogenous depression.

Authors:  P Kragh-Sørensen; M Asberg; C Eggert-Hansen
Journal:  Lancet       Date:  1973-01-20       Impact factor: 79.321

6.  Plasma concentration of nortriptyline and clinical response in depressive illness.

Authors:  G D Burrows; B Davies; B A Scoggins
Journal:  Lancet       Date:  1972-09-23       Impact factor: 79.321

7.  Gas-liquid chromatographic estimation in blood of ICI 58 834.

Authors:  D E Case
Journal:  J Pharm Pharmacol       Date:  1973-10       Impact factor: 3.765

8.  Blood level studies with viloxazine hydrochloride in man.

Authors:  P F Bayliss; D E Case
Journal:  Br J Clin Pharmacol       Date:  1975-06       Impact factor: 4.335

9.  The clinical pharmacology of viloxazine hydrochloride-a new anti-depressant of novel chemical structure.

Authors:  P F Bayliss; S M Duncan
Journal:  Br J Clin Pharmacol       Date:  1974-10       Impact factor: 4.335

10.  The disposition and metabolism of I.C.I. 58,834 (viloxazine) in animals.

Authors:  D E Case; H Illston; P R Reeves; B Shuker; P Simons
Journal:  Xenobiotica       Date:  1975-02       Impact factor: 1.908

View more
  2 in total

Review 1.  Clinical pharmacokinetics of cerebrospinal fluid.

Authors:  M Bonati; J Kanto; G Tognoni
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

2.  Anticonvulsant and proconvulsant properties of viloxazine hydrochloride: pharmacological and pharmacokinetic studies in rodents and the epileptic baboon.

Authors:  B S Meldrum; G M Anlezark; H K Adam; D T Greenwood
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.